BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 29202210)

  • 21. The benefit-to-risk ratio of common treatments in PCOS: effect of oral contraceptives versus metformin on atherogenic markers.
    Christakou C; Kollias A; Piperi C; Katsikis I; Panidis D; Diamanti-Kandarakis E
    Hormones (Athens); 2014; 13(4):488-97. PubMed ID: 25555182
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Adiponectin, interleukin-6, monocyte chemoattractant protein-1, and regional fat mass during 12-month randomized treatment with metformin and/or oral contraceptives in polycystic ovary syndrome.
    Glintborg D; Mumm H; Altinok ML; Richelsen B; Bruun JM; Andersen M
    J Endocrinol Invest; 2014 Aug; 37(8):757-764. PubMed ID: 24906976
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Increased fibrinolytic activity during use of oral contraceptives is counteracted by an enhanced factor XI-independent down regulation of fibrinolysis: a randomized cross-over study of two low-dose oral contraceptives.
    Meijers JC; Middeldorp S; Tekelenburg W; van den Ende AE; Tans G; Prins MH; Rosing J; Büller HR; Bouma BN
    Thromb Haemost; 2000 Jul; 84(1):9-14. PubMed ID: 10928462
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The impact of oral contraceptives and metformin on anti-Müllerian hormone serum levels in women with polycystic ovary syndrome and biochemical hyperandrogenemia.
    Panidis D; Georgopoulos NA; Piouka A; Katsikis I; Saltamavros AD; Decavalas G; Diamanti-Kandarakis E
    Gynecol Endocrinol; 2011 Aug; 27(8):587-92. PubMed ID: 20836726
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Endocrine and metabolic effects of metformin versus ethinyl estradiol-cyproterone acetate in obese women with polycystic ovary syndrome: a randomized study.
    Morin-Papunen LC; Vauhkonen I; Koivunen RM; Ruokonen A; Martikainen HK; Tapanainen JS
    J Clin Endocrinol Metab; 2000 Sep; 85(9):3161-8. PubMed ID: 10999803
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Endocrine and metabolic characteristics in polycystic ovary syndrome.
    Glintborg D
    Dan Med J; 2016 Apr; 63(4):. PubMed ID: 27034186
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Increased thrombin generation in women with polycystic ovary syndrome: A pilot study on the effect of metformin and oral contraceptives.
    Glintborg D; Sidelmann JJ; Altinok ML; Mumm H; Andersen M
    Metabolism; 2015 Oct; 64(10):1272-8. PubMed ID: 26194691
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Metformin improves endothelial function and carotid intima media thickness in patients with PCOS.
    Kaya MG; Yildirim S; Calapkorur B; Akpek M; Unluhizarci K; Kelestimur F
    Gynecol Endocrinol; 2015 May; 31(5):401-5. PubMed ID: 25791462
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effect of six-month use of oral contraceptive pills on plasminogen activator inhibitor-1 & factor VIII among women with polycystic ovary syndrome: An observational pilot study.
    Yousuf SD; Ganie MA; Jeelani S; Mudassar S; Shah ZA; Zargar MA; Amin S; Wani IA; Rashid F
    Indian J Med Res; 2018 Dec; 148(Suppl):S151-S155. PubMed ID: 30964093
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Randomized clinical trial evaluating metformin versus oral contraceptive pills in the treatment of adolescents with polycystic ovarian syndrome.
    Al-Zubeidi H; Klein KO
    J Pediatr Endocrinol Metab; 2015 Jul; 28(7-8):853-8. PubMed ID: 25781525
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparison of spironolactone and spironolactone plus metformin in the treatment of polycystic ovary syndrome.
    Diri H; Karaburgu S; Acmaz B; Unluhizarci K; Tanriverdi F; Karaca Z; Kelestimur F
    Gynecol Endocrinol; 2016; 32(1):42-5. PubMed ID: 26370923
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Retinol-binding protein 4 and insulin resistance in polycystic ovary syndrome.
    Hutchison SK; Harrison C; Stepto N; Meyer C; Teede HJ
    Diabetes Care; 2008 Jul; 31(7):1427-32. PubMed ID: 18390799
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Insulin resistance in polycystic ovarian disease.
    Bhatia V
    South Med J; 2005 Sep; 98(9):903-10; quiz 911-2, 923. PubMed ID: 16217983
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparison of effects of 3 mg drospirenone plus 20 μg ethinyl estradiol alone or combined with metformin or cyproterone acetate on classic metabolic cardiovascular risk factors in nonobese women with polycystic ovary syndrome.
    Fruzzetti F; Perini D; Lazzarini V; Parrini D; Gambacciani M; Genazzani AR
    Fertil Steril; 2010 Oct; 94(5):1793-8. PubMed ID: 19931080
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Metformin versus ethinyl estradiol-cyproterone acetate in the treatment of nonobese women with polycystic ovary syndrome: a randomized study.
    Morin-Papunen L; Vauhkonen I; Koivunen R; Ruokonen A; Martikainen H; Tapanainen JS
    J Clin Endocrinol Metab; 2003 Jan; 88(1):148-56. PubMed ID: 12519844
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Effects of metformin therapy on markers of coagulation disorders in hyperinsulinemic women with polycystic ovary syndrome].
    Serdyńska-Szuster M; Banaszewska B; Spaczyński R; Pawelczyk L
    Ginekol Pol; 2011 Apr; 82(4):259-64. PubMed ID: 21735693
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Increased thrombin-activatable fibrinolysis inhibitor antigen levels as a clue for prothrombotic state in polycystic ovary syndrome.
    Karakurt F; Gumus II; Bavbek N; Kargili A; Koca C; Selcoki Y; Ozbek M; Kosar A; Akcay A
    Gynecol Endocrinol; 2008 Sep; 24(9):491-7. PubMed ID: 18958767
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Reduced circulating levels of chemokine CXCL14 in adolescent girls with polycystic ovary syndrome: normalization after insulin sensitization.
    García-Beltran C; Cereijo R; Quesada-López T; Malpique R; López-Bermejo A; de Zegher F; Ibáñez L; Villarroya F
    BMJ Open Diabetes Res Care; 2020 Feb; 8(1):. PubMed ID: 32107266
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A comparative study to illustrate the benefits of using ethinyl estradiol-cyproterone acetate over metformin in patients with polycystic ovarian syndrome.
    Mhao NS; Al-Hilli AS; Hadi NR; Jamil DA; Al-Aubaidy HA
    Diabetes Metab Syndr; 2016; 10(1 Suppl 1):S95-8. PubMed ID: 26703220
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effects of metformin and ethinyl estradiol-cyproterone acetate on clinical, endocrine and metabolic factors in women with polycystic ovary syndrome.
    Wu J; Zhu Y; Jiang Y; Cao Y
    Gynecol Endocrinol; 2008 Jul; 24(7):392-8. PubMed ID: 18608522
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.